Bisantrene Combination for Resistant AML

Myelogenous Leukemia, Acute Clinical Trial

Official title:

An Open-label, Phase II, Two-stage, Study of Bisantrene(Xantrene) in Combination With Fludarabine and Clofarabine as Salvage Therapy for Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04989335
• Other study ID #: RAC-002
• Status: Recruiting
• Phase: Phase 2
• Start date: August 2, 2021
• Est. completion date: December 1, 2025

Study information

• Verified date: November 2023
• Source: Sheba Medical Center
• Contact: Arnon Nagler, MD
• Phone: 972-3-530-58-30
• Email: Arnon.Nagler[@]sheba.health.gov.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An Open-label, Phase II, Two-stage, Study of Xantrene® (Bisantrene) in combination with Fludarabine and Clofarabine as Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Lead-in stage: up to 12 (up to 2 cohorts in a 3+3 dose escalation design) Efficacy stage: up to 17 (Simon 2-stage design 9+8) Study Objectives: - Confirm safety and tolerability of the combination regimen - Time to response with combination treatment - Overall survival The treatment regimen will comprise daily IV infusion of Fludarabine (Flu), Clofarabine (Clo) and Bisantrene (Xan) administered via central venous line and controlled-rate infusion pump with a 1-hour break between each agent infusion, amounting to a total of 6 hours for each daily FluCloXan treatment in the following sequence: - First, infusion over 60 minutes of Fludarabine (Flu) at 10 mg/m2 - Followed by infusion of Clofarabine (Clo) at 30 mg/m2 over 60 minutes - Followed by infusion of Bisantrene (Xan) at 250 mg/m2 over 2 hours. One cycle will comprise daily IV infusion of the combination treatment course for 4 or 5 consecutive days and rest period to between Day 30 and Day 42, based on patient performance and disease status.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 29
• Est. completion date: December 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per national regulations.

2. Age 18 -65 (inclusive) years

3. Diagnosis of AML by World Health Organization (WHO) classification (WHO, 2016) and have received at least one line of therapy prior to enrollment into this study.

4. Eastern Cooperative Oncology Group (ECOG) performance status = 2.0

5. Life expectancy = 3 months.

6. Adequate organ function as evidenced by serum total bilirubin = 2.0 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =4 × the upper limit of normal (ULN), serum albumin >2.8 g/dL, serum creatinine =2 mg/dL.

7. Cardiac ejection fraction =50%, assessed by 2-Dimensional echocardiogram.

8. Pulmonary function =50% assessed by diffusing capacity for carbon monoxide (DLCO), and any clinically significant decrease in DLCO must not be caused by infection.

9. Negative for serum markers for HIV, Hepatitis -B, -C, and HTLV-1

10. Clinically significant non-hematologic toxicity after prior chemotherapy has recovered to Grade 1 per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

11. Females must be surgically or biologically sterile or postmenopausal (amenorrhoeic for at least 12 months) or if of childbearing potential, must have a negative urine or serum pregnancy test within 14 days before study entry, and must agree to use an adequate method of contraception, i.e. barrier method, during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception, i.e. barrier method, during the study until 30 days after the last treatment.

Exclusion Criteria:

1. Acute promyelocytic leukemia (APML, APL) M3 subtype of AML.

2. Other active malignancy (including other hematologic malignancies) or other malignancy within the last 12 months except non-melanoma skin cancer or cervical intraepithelial neoplasia.

3. Prior or current therapy:

1. Hydroxyurea or other oral medications to reduce blast count within 72 hours before the first dose of study drug

2. Treatment with an investigational agent within 14 days before the first dose of study drug, or not recovered from all acute effects of previous investigational therapy

3. Last treatment was with a drug of long elimination half-life (e.g. enasidenib), as such a wash out period 5x elimination half-life is necessary prior to enrollment

4. For patients who have undergone hematopoietic stem cell transplantation (HSCT), procedure-related medications (e.g. immunosuppressive therapy) administered within 2 weeks prior to first dose of study drug.

5. Any medical, psychological, or social condition that may interfere with study participation or compliance or may compromise the patient's safety in the opinion of the investigator.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelogenous Leukemia, Acute

Intervention

Drug:
• Bisantrene
Combined escalated dose chemotherapy
• Fludarabine
Combined escalated dose chemotherapy
• Clofarabine
Combined escalated dose chemotherapy

Locations

Country	Name	City	State
Israel	Chaim Sheba Medical Center	Ramat Gan

Sponsors (2)

Lead Sponsor	Collaborator
Sheba Medical Center	Race Oncology Ltd

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	MRD status	To determine the MRD status of patients post completion of FluCloXan. MRD will be asset in patients with defiant mutations by Polymerase Chain Techniques(PCR).	12 months
Primary	The recommended Phase 2 dose (RP2D) , assessed by the number of treatment days of FluCloXan		12 months
Primary	The maximum tolerated dose (MTD) of Bisantre in mg per day	To evaluate safety and tolerability	12 months
Primary	The overall response rate (ORR)	Overall Response Rate (ORR) defined as the proportion of patients with complete remission (CR) and complete remission with incomplete blood count recovery (CRi) between Day 30 to Day 42.	between Day 30 to Day 42.
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.	Confirm safety and tolerability of the combination regimen.	12 months
Secondary	Time of respons in months	Number of months for each patient with no evidence of diseases.	12 months
Secondary	Overall survival	Median surviving months for each patients.	12 months